R
Rakesh K. Jain
Researcher at Harvard University
Publications - 1528
Citations - 198912
Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.
Papers
More filters
Journal ArticleDOI
Combining two strategies to improve perfusion and drug delivery in solid tumors
TL;DR: A mathematical model is developed to guide the optimal use of vascular normalization and stress-alleviation to improve tumor perfusion and delivery of drugs and reveals an optimal perfusion region when vessels are uncompressed, but not very leaky.
Next-generation in vivo optical imaging with short-wave infrared quantum dots
Lars Riedemann,Alexander Bartelt,Frank B. Jaworski,Jonas Kloepper,Joerg Heeren,Peter T. C. So,Dai Fukumura,Rakesh K. Jain,Oliver T. Bruns,Thomas S. Bischof,Daniel K. Harris,Daniel Franke,Yanxiang Shi,Jessica A. Carr,Christopher J. Rowlands,Mark W. Wilson,Ou Chen,He Wei,Gyu Weon Hwang,Daniel M Montana Fernandez,Igor Coropceanu,Odin B. Achorn,Klavs F. Jensen,Moungi G. Bawendi +23 more
TL;DR: In this paper, a class of high-quality SWIR-emissive indium-arsenide-based quantum dots (QDs) are introduced for various functional imaging applications, and that exhibit narrow and size-tunable emission and a dramatically higher emission quantum yield than previously described SWIR probes.
Journal ArticleDOI
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models
Ioanna Keklikoglou,Chiara Cianciaruso,Esra Güç,Mario Leonardo Squadrito,Laura Spring,Simon Tazzyman,Lore Lambein,Amanda Poissonnier,Gino B. Ferraro,Caroline Baer,Antonino M. Cassarà,Alan Guichard,M. Luisa Iruela-Arispe,M. Luisa Iruela-Arispe,Claire E. Lewis,Lisa M. Coussens,Aditya Bardia,Rakesh K. Jain,Jeffrey W. Pollard,Jeffrey W. Pollard,Michele De Palma +20 more
TL;DR: It is shown that two classes of cytotoxic drugs broadly employed in pre-operative (neoadjuvant) breast cancer therapy, taxanes and anthracyclines, elicit tumour-derived EVs with enhanced pro-metastatic capacity.
Journal ArticleDOI
Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside.
TL;DR: The mechanics of the solid and fluid components of a tumor are discussed, with a focus on how they impede the transport of therapeutic agents and create an abnormal tumor microenvironment that fuels tumor progression and treatment resistance.
Journal ArticleDOI
Delivery of Molecular Medicine to Solid Tumors
TL;DR: Jain proposes a three-part strategy for overcoming this obstacle to successful treatment of tumors.